Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1

Chamutal Gur, Naseem Maalouf, Amjad Shhadeh, Orit Berhani, Bernhard B. Singer, Gilad Bachrach, Ofer Mandelboim*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Abstract

Fusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatum in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatum binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatum also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors.

Original languageAmerican English
Article numbere1581531
JournalOncoImmunology
Volume8
Issue number6
DOIs
StatePublished - 3 Jun 2019

Bibliographical note

Publisher Copyright:
© 2019, © 2019 Taylor & Francis Group, LLC.

Keywords

  • CEACAM1
  • Fusobacterium nucleatum
  • inhibition of killing

Fingerprint

Dive into the research topics of 'Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1'. Together they form a unique fingerprint.

Cite this